[HTML][HTML] Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line …
E Bria, M Milella, F Cuppone, S Novello, A Ceribelli… - Annals of oncology, 2011 - Elsevier
Background Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) are
effective as first-line treatment of advanced non-small-cell lung cancer patients with EGFR …
effective as first-line treatment of advanced non-small-cell lung cancer patients with EGFR …
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus …
Purpose We examined the impact of different epidermal growth factor receptor (EGFR)
mutations and clinical characteristics on progression-free survival (PFS) in patients with …
mutations and clinical characteristics on progression-free survival (PFS) in patients with …
[HTML][HTML] Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort
I Okamoto, S Morita, N Tashiro, F Imamura, A Inoue… - Lung Cancer, 2018 - Elsevier
Objectives Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have
been shown to be effective for the treatment of EGFR mutation-positive non-small cell lung …
been shown to be effective for the treatment of EGFR mutation-positive non-small cell lung …
Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a …
N Zhao, X Zhang, H Yan, J Yang, Y Wu - Lung Cancer, 2014 - Elsevier
Background EGFR mutation status is closely related to the efficacy of EGFR-TKIs in
advanced non-small cell lung cancer (NSCLC). EGFR-TKIs have become the standard first …
advanced non-small cell lung cancer (NSCLC). EGFR-TKIs have become the standard first …
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non–small-cell lung cancer: a meta-analysis of 13 randomized trials
F Petrelli, K Borgonovo, M Cabiddu, S Barni - Clinical lung cancer, 2012 - Elsevier
Advanced non–small-cell lung cancer (NSCLC) harboring activating mutations of epidermal
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …
The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR …
I Okamoto, T Mitsudomi, K Nakagawa… - … advances in medical …, 2010 - journals.sagepub.com
Gefitinib and erlotinib, small-molecule tyrosine kinase inhibitors (TKIs) of the epidermal
growth factor receptor (EGFR), were the first molecularly targeted agents to become …
growth factor receptor (EGFR), were the first molecularly targeted agents to become …
First-generation EGFR-TKI plus chemotherapy versus EGFR-TKI alone as first-line treatment in advanced NSCLC with EGFR activating mutation: a systematic review …
Q Wu, W Luo, W Li, T Wang, L Huang, F Xu - Frontiers in Oncology, 2021 - frontiersin.org
Objective The aim of this meta-analysis was to evaluate efficacy and toxicity of epidermal
growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in combination with …
growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in combination with …
The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutation
A Sgambato, F Casaluce, P Maione… - Current medicinal …, 2012 - ingentaconnect.com
Lung cancer continues to be the leading cause of cancer death worldwide. Among lung
cancers, 80% are classified as nonsmall-cell lung cancer (NSCLC) and are mostly …
cancers, 80% are classified as nonsmall-cell lung cancer (NSCLC) and are mostly …
Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer …
It is controversial whether there is efficacy or safety benefit of epidermal growth factor
receptor-tyrosine kinase inhibitor (EGFR-TKI) in advanced EGFR-mutated non-small cell …
receptor-tyrosine kinase inhibitor (EGFR-TKI) in advanced EGFR-mutated non-small cell …
American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non …
VL Keedy, S Temin, MR Somerfield… - Journal of clinical …, 2011 - ascopubs.org
Purpose An American Society of Clinical Oncology (ASCO) provisional clinical opinion
(PCO) offers timely clinical direction to ASCO's membership following publication or …
(PCO) offers timely clinical direction to ASCO's membership following publication or …
相关搜索
- kinase inhibitor egfr tki
- meta analysis egfr tki
- meta analysis kinase inhibitor
- nsclc patients egfr tkis
- meta analysis nsclc patients
- receptor tyrosine egfr tki
- meta analysis receptor tyrosine
- tkis alone egfr mutation
- receptor tyrosine kinase inhibitor
- growth factor egfr tki
- growth factor kinase inhibitor
- meta analysis lung cancer
- meta analysis growth factor
- world treatment patient cohort
- efficacy and safety egfr tki
- efficacy and safety kinase inhibitor